Accordingly, there are reports of cases not responding to osimertinib or rociletinib, which showed EGFR-, ERBB2- or MET-amplification, or SCLC transformation in samples obtained before or after very few weeks of treatment [29,242]. Here, EGFR is linked to small cell lung carcinoma.